EGFR and breast cancer: Since the aim of cancer therapy is to reduce the growth rate of cancer cells, and trastuzumab resistant breast cancer cells escape cell cycle arrest during treatment, we focused on a protein network that connects ERBB signaling to G1/S phase transition, in order to determine new potential targets for perturbation.